TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34659237

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 2263
Study: 32383125

Group type: COMPARATOR
Intervention: Hydroxychloroquine for PEP
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Hydroxychloroquine for PET
Number of subjects: 1500
Study: 35666937

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126
Study: 34433377

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left DLPFC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over left DLPFC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 34196397

Group type: EXPERIMENTAL
Intervention: SNOT-22
Number of subjects: 113
Study: 32679218

Group type: EXPERIMENTAL
Intervention: Celiac disease (CD) patients
Number of subjects: 48119

Group type: COMPARATOR
Intervention: Reference individuals
Number of subjects: 48119
Study: 35080060

Group type: EXPERIMENTAL
Intervention: Closed-loop brain state-dependent stimulation in the form of auditory tones (STIM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No tones (SHAM)
Number of subjects: 24
Study: 33710261

Group type: EXPERIMENTAL
Intervention: 1 g Schisandra chinensis Baillon extract (SCe) daily for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 32415923

Group type: EXPERIMENTAL
Intervention: Calcitriol combined with sevelamer carbonate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Calcitriol alone
Number of subjects: 180
Study: 36307427

Group type: EXPERIMENTAL
Intervention: Magnesium oxide 250 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 34286837

Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention (PAL-I) for 3 months
Number of subjects: 15
Study: 32092321

Group type: EXPERIMENTAL
Intervention: iNO 30 μg/kg ideal body weight/h
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: iNO 30, 45, and 75
Number of subjects: 41
Study: 33065955

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (single-dose studies)
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (repeat-dose studies)
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Placebo (single-dose studies)
Number of subjects: 1377
Study: 35045900

Group type: EXPERIMENTAL
Intervention: Brief video-based intervention at day 1 and booster video at day 14
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Brief video-based intervention at day 1 only
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 350
Study: 32673228

Group type: EXPERIMENTAL
Intervention: GRASP framework
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (derivation publications)
Number of subjects: 194
Study: 36208242

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with antivirals (including recombinant interferon alpha-2b and CHOP therapy, zidovudine combined with CHOP therapy, CHOP regimen combined with interferon and zidovudine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chemotherapy alone (CHOP therapy)
Number of subjects: 49
Study: 34684407

Group type: EXPERIMENTAL
Intervention: 6 g of hydrolyzed pine nut oil (PNO-FFA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of 3 g hydrolyzed pine nut oil and 3 g olive oil (PNO-OO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both oil treatments (PNO-FFA and PNO-OO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No oil
Number of subjects: 9
Study: 32630079

Group type: EXPERIMENTAL
Intervention: Lipigo®
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33129990

Group type: EXPERIMENTAL
Intervention: Digital Study using Eureka platform
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Geofencing for hospitalization tracking
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Monthly digital hospitalization surveys
Number of subjects: 930
Study: 32151115

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neostigmine with atropine
Number of subjects: 80
Study: 36223366

Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA) trial (19.9 ± 0.2 kcal/kg fat free mass [FFM]/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal energy availability (NEA) trial (46.4 ± 0.1 kcal/kg FFM/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA) trial
Number of subjects: 10
Study: 34020123

Group type: EXPERIMENTAL
Intervention: Gait perturbation protocol (treadmill-based, 10-week therapy)
Number of subjects: 24
Study: 36396308

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32467037

Group type: EXPERIMENTAL
Intervention: Subclavian vein group
Number of subjects: 415

Group type: COMPARATOR
Intervention: Internal jugular vein group
Number of subjects: 415
Study: 32787934

Group type: EXPERIMENTAL
Intervention: Prefilled pen
Number of subjects: 23
Study: 35932584

Group type: EXPERIMENTAL
Intervention: Multimodal subtyping analysis
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Motor variables and gray matter volume in the right medial postcentral gyrus
Number of subjects: 95
Study: 33444689

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS) via tragus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS) via cymba conchae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation via earlobe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tVNS (all areas combined)
Number of subjects: 0
Study: 32919098

Group type: EXPERIMENTAL
Intervention: Personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Peer recovery support service - PRSS)
Number of subjects: 80
Study: 36497804

Group type: EXPERIMENTAL
Intervention: ready4life mobile app-based coaching program for 16 weeks
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1351
Study: 34044671

Group type: EXPERIMENTAL
Intervention: Noncoplanar IMRT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coplanar IMRT
Number of subjects: 48
Study: 32119700

Group type: EXPERIMENTAL
Intervention: New Metal Strips
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ortho‐Strips
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: OS discs
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Safe‐Tipped Bur Kit
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 65
Study: 36317783

Group type: EXPERIMENTAL
Intervention: 10 mg of CIS43LS per kilogram
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 40 mg of CIS43LS per kilogram
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 32457106

Group type: EXPERIMENTAL
Intervention: SUBA™-Itraconazole (S-ITZ) 2x65 mg TID for 3 days and once on day 4
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SUBA™-Itraconazole (S-ITZ) 2x65 mg BID for 14 days and a last dose on day 15
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional Itraconazole (C-ITZ) 2x100 mg TID for 3 days and once on day 4
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional Itraconazole (C-ITZ) 2x100 mg BID for 14 days and a last dose on day 15
Number of subjects: 31
Study: 35610308

Group type: EXPERIMENTAL
Intervention: FCB (Fludarabine + Clofarabine + Busulfan)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Flu-Bu (Fludarabine + Busulfan)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: FCB
Number of subjects: 250

Group type: COMPARATOR
Intervention: Flu-Bu
Number of subjects: 250
Study: 33386619

Group type: EXPERIMENTAL
Intervention: Forgiveness intervention (twice-a-week sessions for 4 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Forgiveness intervention
Number of subjects: 16
Study: 35917453

Group type: EXPERIMENTAL
Intervention: GIL + AZA
Number of subjects: 123

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 123
Study: 34491220

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 0
Study: 32657141

Group type: EXPERIMENTAL
Intervention: Differentiated expressed circular RNAs (DECs) in PDGA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top 20 DECs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hsa_circRNA_0077837
Number of subjects: 0
Study: 35485617

Group type: EXPERIMENTAL
Intervention: Teach-back method education delivered individually in three sessions of approximately 60 minutes at one-day intervals.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no training provided).
Number of subjects: 58
Study: 32835356

Group type: EXPERIMENTAL
Intervention: 5FU
Number of subjects: 34640

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 34640

Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 34640

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 34640

Group type: EXPERIMENTAL
Intervention: capecitabine
Number of subjects: 34640
Study: 33608762

Group type: EXPERIMENTAL
Intervention: Personal feedback (PF)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Automated feedback (AF)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 203
Study: 32981348

Group type: EXPERIMENTAL
Intervention: Genetic increase of 10 mm Hg in diastolic blood pressure
Number of subjects: 7642

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 7642

Group type: EXPERIMENTAL
Intervention: 29-variant polygenic risk score (PRS)
Number of subjects: 7642

Group type: EXPERIMENTAL
Intervention: PRS with family history and smoking risk factors
Number of subjects: 7642
Study: 34011467

Group type: EXPERIMENTAL
Intervention: Active rTMS (6000 pulses at 20 Hz)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 29
Study: 33011099

Group type: EXPERIMENTAL
Intervention: Lenabasum 1 mg QD (Weeks 1–4)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg QD (Weeks 1–4)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg QD (Weeks 5–12)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg BID (Weeks 5–12)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (Weeks 1–4 and 5–12)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lenabasum
Number of subjects: 89
Study: 33609425

Group type: EXPERIMENTAL
Intervention: 9-week nurse-led Internet-based cognitive behavioural therapy for insomnia (I-CBTI) with support
Number of subjects: 48

Group type: COMPARATOR
Intervention: Internet-based self-study programme without support (control group)
Number of subjects: 48
Study: 32267724

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 7 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 35063791

Group type: EXPERIMENTAL
Intervention: Biomass cooking fuel
Number of subjects: 600

Group type: COMPARATOR
Intervention: Not applicable (control group using other cooking fuels)
Number of subjects: 600
Study: 33814126

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day
Number of subjects: 318

Group type: COMPARATOR
Intervention: GnRH antagonist (ganirelix 0.25 mg/day)
Number of subjects: 318
Study: 34489288

Group type: EXPERIMENTAL
Intervention: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP), a 12-week cognitive behavioural therapy (CBT) and motivational interviewing programme delivered via video-conferencing.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP)
Number of subjects: 220
Study: 33176842

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily for 104 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 0
Study: 36085211

Group type: EXPERIMENTAL
Intervention: Active DCP
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Collaborative DCP
Number of subjects: 761

Group type: COMPARATOR
Intervention: Passive DCP
Number of subjects: 761
Study: 34152099

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 33876178

Group type: EXPERIMENTAL
Intervention: Adequate gestational weight gain (GWG)
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Inadequate gestational weight gain (GWG)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: GWG velocity (kg/wk)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Increase of 0.1 kg/wk in maternal GWG
Number of subjects: 2331
Study: 32767227

Group type: EXPERIMENTAL
Intervention: Mobile platform measuring pain, emotions, and bodily feelings
Number of subjects: 65
Study: 33434512

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 34510214

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) training
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Progressive exercise program (PEP)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard primary care management (PCM)
Number of subjects: 128
Study: 34391267

Group type: EXPERIMENTAL
Intervention: Pain inducing massage to the neck
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold pressor task to the hand
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pain free massage to the neck
Number of subjects: 60
Study: 32951733

Group type: EXPERIMENTAL
Intervention: Vaginal cream containing aqueous extract of Achillea millefolium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal cream clotrimazole 1%
Number of subjects: 80
Study: 36170737

Group type: EXPERIMENTAL
Intervention: Psychiatrists (PSY)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-Psychiatrist Healthcare Professionals (NPHP)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Obstetricians-Gynecologists (NPHP subgroup)
Number of subjects: 141

Group type: COMPARATOR
Intervention: General Practitioners (NPHP subgroup)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Pediatricians (NPHP subgroup)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Neurologists (NPHP subgroup)
Number of subjects: 141
Study: 34006070

Group type: EXPERIMENTAL
Intervention: Xenogeneic cortical plates (XCP group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Autogenous cortical plates (ACP group)
Number of subjects: 19
Study: 33722947

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 969
Study: 33367487

Group type: EXPERIMENTAL
Intervention: Diabetes on no medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes on non-insulin antidiabetic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 0
Study: 33032686

Group type: EXPERIMENTAL
Intervention: RFC ablation with prior application of EMLA (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RFC ablation without prior application of EMLA (Group B)
Number of subjects: 60
Study: 33301361

Group type: EXPERIMENTAL
Intervention: Standard ablation plus elimination of distal CS to LA connections
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard ablation (pulmonary vein isolation and nonpulmonary vein trigger ablation)
Number of subjects: 35
Study: 32423577

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) training with low weight
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-BFR extremity
Number of subjects: 24
Study: 35088609

Group type: EXPERIMENTAL
Intervention: IMB model-based education (10-minute online sessions for 7 days)
Number of subjects: 3739
Study: 34332817

Group type: EXPERIMENTAL
Intervention: Reduction and association of the scaphoid and lunate (RASL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three-ligament tenodesis (TLT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anatomic front and back (ANAFAB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TLT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: RASL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ANAFAB
Number of subjects: 15
Study: 35105626

Group type: EXPERIMENTAL
Intervention: Diquafosol sodium 3% eye-drops
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hyaluronic acid 0.1% eye-drops
Number of subjects: 42
Study: 34091569

Group type: EXPERIMENTAL
Intervention: Walking activity
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active group
Number of subjects: 69
Study: 36330670

Group type: EXPERIMENTAL
Intervention: Block group (collagenated soft-block-type BCP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Particle group (particulate BCP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (regardless of BCP type)
Number of subjects: 35
Study: 32191203

Group type: EXPERIMENTAL
Intervention: Assigned Evidence‐Based Medicine (EBM) articles and Rosh Review questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textbook readings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New curriculum (question-based learning and EBM articles)
Number of subjects: 0
Study: 34250636

Group type: EXPERIMENTAL
Intervention: Mindfulness-based childbirth and parenting (MBCP)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Enhanced care as usual (ECAU)
Number of subjects: 141
Study: 33934647

Group type: EXPERIMENTAL
Intervention: Asymmetrical tibial design (Persona PS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Symmetrical tibial design (NexGen LPS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both designs (Asymmetrical and Symmetrical)
Number of subjects: 75
Study: 33893022

Group type: EXPERIMENTAL
Intervention: ABSORB bioresorbable vascular scaffold (BVS)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents
Number of subjects: 286
Study: 33051385

Group type: EXPERIMENTAL
Intervention: Sickness absence due to MDD
Number of subjects: 158813

Group type: EXPERIMENTAL
Intervention: More severe MDD and longer duration of sickness absence
Number of subjects: 158813
Study: 35348360

Group type: EXPERIMENTAL
Intervention: Standard of care interventions
Number of subjects: 0
Study: 33429797

Group type: EXPERIMENTAL
Intervention: Pelvic floor electrical stimulation (PFES)
Number of subjects: 33
Study: 32944871

Group type: EXPERIMENTAL
Intervention: Yeast-fermented de-hulled rice (YDR) with sweet grass hay (SGH) at 50-75:50-25 ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Yeast-fermented de-hulled rice (YDR) with untreated rice straw (RS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sweet grass hay (SGH) with YDR ratios
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Different R:YDR ratios (100:0, 75:25, 50:50, 25:75)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sweet grass hay (SGH) and R:YDR ratios
Number of subjects: 8
Study: 34387244

Group type: EXPERIMENTAL
Intervention: Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) didactic, online module on TeamSTEPPS RRT program, presimulation and postsimulation experience
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RRT rubric assessment
Number of subjects: 24
Study: 32921117

Group type: EXPERIMENTAL
Intervention: Carbohydrate administration 3 hours before surgery
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 35177019

Group type: EXPERIMENTAL
Intervention: ACORN intervention + Treatment as usual (TAU)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114
Study: 33368937

Group type: EXPERIMENTAL
Intervention: Heat-patch treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 33362252

Group type: EXPERIMENTAL
Intervention: GlycoCheck system measurements
Number of subjects: 42
Study: 36131308

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB) of local anaesthetic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion of local anaesthetic
Number of subjects: 60
Study: 34099033

Group type: EXPERIMENTAL
Intervention: Group skills treatment (stepped-care structured psychological group treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 32816189

Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and resistance training 3×/wk)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 37
Study: 34403658

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg + TCS
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg + TCS
Number of subjects: 901

Group type: COMPARATOR
Intervention: PBO + TCS
Number of subjects: 901
Study: 33693732

Group type: EXPERIMENTAL
Intervention: Simultaneous entry using PIQNIQ
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Photo-assisted recall using PIQNIQ
Number of subjects: 132

Group type: COMPARATOR
Intervention: 24HR (interviewer-assisted 24-h recall)
Number of subjects: 132
Study: 32626889

Group type: EXPERIMENTAL
Intervention: Oral implant restoration (experimental group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine methods (control group)
Number of subjects: 84
Study: 36311870

Group type: EXPERIMENTAL
Intervention: IV TXA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local infiltration of TXA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TXA (both IV and local)
Number of subjects: 90
Study: 33576812

Group type: EXPERIMENTAL
Intervention: Bimagrumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0